Mersana Therapeutics, Inc (MRSN) insider trading
Every open-market stock purchase and sale by Mersana Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $762 over the last 12 months (1 sale). No open-market buys.
- Last insider buy: Andrew A. F. Hack (Director), $47.2K, 4 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $762 (1 sale). Last close $29.08 on Jan 4, 2026.
Recent MRSN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $2.7M |
| Jan 6, 2026 | Timothy B Lowinger (VP) | Sold (not open market) | $2.6M |
| Jan 6, 2026 | Brian DeSchuytner (CFO) | Sold (not open market) | $2.2M |
| Jan 6, 2026 | Alejandra Carvajal (C-suite exec) | Sold (not open market) | $1.9M |
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $1.8M |
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $1.7M |
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $1.4M |
| Jan 6, 2026 | Brian DeSchuytner (CFO) | Sold (not open market) | $967K |
| Jan 6, 2026 | Martin H. Huber Jr. (CEO) | Sold (not open market) | $920K |
| Jan 6, 2026 | Timothy B Lowinger (VP) | Sold (not open market) | $892K |
| Jan 6, 2026 | Mohan Bala (VP) | Sold (not open market) | $795K |
| Jan 6, 2026 | Alejandra Carvajal (C-suite exec) | Sold (not open market) | $746K |
| Jan 6, 2026 | Allene M. Diaz (Director) | Sold (not open market) | $720K |
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $714K |
| Jan 6, 2026 | Brian DeSchuytner (CFO) | Sold (not open market) | $711K |
| Jan 6, 2026 | Mohan Bala (VP) | Sold (not open market) | $703K |
| Jan 6, 2026 | Brian DeSchuytner (CFO) | Sold (not open market) | $662K |
| Jan 6, 2026 | Timothy B Lowinger (VP) | Sold (not open market) | $601K |
| Jan 6, 2026 | Alejandra Carvajal (C-suite exec) | Sold (not open market) | $598K |
| Jan 6, 2026 | Mohan Bala (VP) | Sold (not open market) | $571K |
| Jan 6, 2026 | Martin H. Huber Jr. (CEO) | Sold (not open market) | $564K |
| Jan 6, 2026 | Timothy B Lowinger (VP) | Sold (not open market) | $561K |
| Jan 6, 2026 | Brian DeSchuytner (CFO) | Sold (not open market) | $558K |
| Jan 6, 2026 | Anna Protopapas (Director) | Sold (not open market) | $536K |
| Jan 6, 2026 | Timothy B Lowinger (VP) | Sold (not open market) | $508K |
Who's trading MRSN
- Anna Protopapas, Director: other filings, last Jan 6, 2026
- Mohan Bala, C-suite exec: sold $762 (1 sale), last Jan 6, 2026
- Alejandra Carvajal, C-suite exec: other filings, last Jan 6, 2026
- Brian DeSchuytner, CFO: other filings, last Jan 6, 2026
- Willard H Dere, Director: other filings, last Jan 6, 2026
- Allene M. Diaz, Director: other filings, last Jan 6, 2026
- Ashish Mandelia, C-suite exec: other filings, last Jan 6, 2026
- Lawrence M Alleva, Director: other filings, last Jan 6, 2026
- Andrew A. F. Hack, Insider: other filings, last Jan 6, 2026
- Kristen Hege, Director: other filings, last Jan 6, 2026
- Martin H. Huber Jr., CEO: other filings, last Jan 6, 2026
- Timothy B Lowinger, VP: other filings, last Jan 6, 2026
- David M Mott, Director: other filings, last Jan 6, 2026
Get free alerts when an insider at Mersana Therapeutics, Inc files a new trade →